Mikael Brink

Mikael Brink

Auto-generated profile, based on publicly available information

Mikael Brink

Department of Public Health and Clinical Medicine, Rheumatology Umeå University, Umeå, Sweden

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2013 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MBMikael Brink
Mikael Brink
MHMonika Hansson
Monika Hansson
LMLinda Mathsson
Linda Mathsson
PJPer‐Johan Jakobsson
Per‐Johan Jakobsson
RHRikard Holmdahl
Rikard Holmdahl
SRSolbritt Rantapää-Dahlqvist
Solbritt Rantapää-Dahlqvist
Objective: The presence of antibodies against cyclic citrullinated peptides has been demonstrated to precede the onset of symptoms of rheumatoid arthritis (RA) by several years. The aim of this study was to analyze antibodies against 10 citrullinated autoantigen‐derived peptides for reactivity before the onset of RA symptoms.Methods: A case–control study was conducted within the Medical Biobank of Northern Sweden. The study was performed in 409 individuals, 386 of whom donated 717 blood samples before the onset of symptoms of RA (pre‐patients). The median period of time predating the onset of RA was 7.4 years. A total of 1,305 population‐based control subjects were also studied. Antibodies to 10 citrullinated peptides, fibrinogen α573 (Fibα573), Fibα591, Fibβ36–52, Fibβ72, Fibβ74, α‐enolase (citrullinated α‐enolase peptide 1 [CEP‐1]), triple‐helical type II collagen peptide C1 (citC1III), filaggrin, vimentin 2–17 (Vim2–17), and Vim60–75, were analyzed using a microarray system.Results: The fluorescence intensity of antibodies against Fibβ36–52, Fibβ74, CEP‐1, citC1III, and filaggrin was significantly increased in pre‐patients compared with controls (P < 0.001). The levels of the earliest‐detectable antibodies (Fibα591 and Vim60–75) fluctuated over time, with only a slight increase after the onset of disease. The frequency of antibodies against Fibβ36–52, CEP‐1, and filaggrin increased gradually, reaching the highest levels before symptom onset. The frequency of a cluster of antibodies, citC1III, Fibα573, and Fibβ74, increased only slightly before the onset of symptoms but increased prominently after disease onset. The odds ratio for the development of RA in individuals expressing both CEP‐1 and Fibβ36–52 antibodies (using data from samples obtained <3.35 years predating symptom onset) was 40.4 (95% confidence interval 19.8–82.3) compared with having either antibody alone.Conclusion: Development of an immune response toward citrullinated peptides is initially restricted but expands with time to induce a more specific response, with levels, particularly those of antibodies against CEP‐1, Fibβ36–52, and filaggrin, increasing during the predating time period closer to the onset of symptoms.

1 May 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JLJoyce Lübbers
Joyce Lübbers
MBMikael Brink
Mikael Brink
LSLotte A van de Stadt
Lotte A van de Stadt
SVSaskia Vosslamber
Saskia Vosslamber
JWJohn G Wesseling
John G Wesseling
CVCornelis L Verweij
Cornelis L Verweij
Objectives To validate the presence and demonstrate the clinical value of the type I interferon (IFN)-signature during arthritis development. Method In 115 seropositive arthralgia patients who were followed for the development of arthritis (Amsterdam Reade cohort), and 25 presymptomatic individuals who developed rheumatoid arthritis (RA) later, and 45 population-based controls (Northern Sweden cohort), the expression levels of 7 type I IFN response genes were determined with multiplex qPCR and an IFN-score was calculated. The diagnostic performance of the IFN-score was evaluated using Cox regression and Receiver Operating Characteristics (ROC)-curve analysis. Results In 44 of the 115 at-risk individuals (38%) from the Amsterdam Reade cohort, arthritis developed after a median period of 8 months (IQR 5–13). Stratification of these individuals based on the IFN-score revealed that 15 out of 25 IFNhigh individuals converted to arthritis, compared with 29 out of 90 IFNlow individuals (p=0.011). In the Northern Sweden cohort, the level of the IFN-score was also significantly increased in presymptomatic individuals who developed RA compared with population-based controls (p=0.002). Cox regression analysis of the Amsterdam Reade cohort showed that the hazard ratio (HR) for development of arthritis was 2.38 (p=0.008) for IFNhigh at-risk individuals after correction for anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). The ROC-curve area under the curve (AUC) for the IFN-score combined with ACPA and RF in the prediction of arthritis was 78.5% (p=0.0001, 95% CI 0.70 to 0.87). Conclusions The results demonstrated clinical utility for the IFN-signature as a biomarker in the prediction of arthritis development.

7 February 2015 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MBMikael Brink
Mikael Brink
MVMarije K Verheul
Marije K Verheul
JRJohan Rönnelid
Johan Rönnelid
EBEwa Berglin
Ewa Berglin
Rikard HolmdahlRikard Holmdahl
Rikard Holmdahl
SRSolbritt Rantapää-Dahlqvist
Solbritt Rantapää-Dahlqvist
Introduction: The presence of a new autoantibody system, anti-carbamylated protein (anti-CarP) antibodies, has been identified in rheumatoid arthritis (RA). The presence of anti-CarP antibodies was evaluated in samples taken from individuals who subsequently developed RA before and after onset of symptoms and related to previously analysed antibodies against citrullinated peptides (ACPA specificities) and anti-CCP2. Methods: A total of 252 individuals, with 423 samples from before onset of symptoms of RA, and 197 population controls were identified as donors to the Medical Biobank of Northern Sweden; 192 of them were also sampled at the time of diagnosis. All samples were analysed for anti-CarP IgG and anti-CCP2 antibodies using ELISAs. Ten different antibody reactivities against citrullinated antigens (ACPA specificities) were analysed using a custom-made microarray based on the ImmunoCAP ISAC system (Phadia). Results: The concentration of anti-CarP antibodies was significantly increased in the pre-symptomatic individuals compared with controls (P <0.001) and also increased significantly after disease onset (P <0.001). The sensitivity for anti-CarP antibodies in the pre-symptomatic individuals was 13.9% (95% CI: 11 to 17.6) and 42.2% (95% CI: 35.4 to 49.3) following development of RA. Anti-CarP antibody positivity was found in 5.1% to 13.3% of individuals negative for anti-CCP2 or ACPA specificities. Presence of anti-CarP antibodies was significantly related to radiological destruction at baseline, at 24 months and also to radiological change (P <0.05, all). Conclusions: The results indicate that anti-CarP antibodies are associated with disease development, even after adjusting for the presence of different ACPA fine specificities, and in anti-CCP2 negative individuals and contribute to the identification of a subset of patients with worse radiological progression of the disease independent of ACPA.

16 September 2018 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
MVMarije K. Verheul
Marije K. Verheul
SBStefan Böhringer
Stefan Böhringer
MDMyrthe A. M. van Delft
Myrthe A. M. van Delft
JJJonathan D. Jones
Jonathan D. Jones
WRWilliam F. C. Rigby
William F. C. Rigby
LTLeendert A. Trouw
Leendert A. Trouw

9 February 2016 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MBMikael Brink
Mikael Brink
MHMonika Hansson
Monika Hansson
LMLinda Mathsson-Alm
Linda Mathsson-Alm
Priyantha WijayatungaPriyantha Wijayatunga
Priyantha Wijayatunga
MVMarije K. Verheul
Marije K. Verheul
SRSolbritt Rantapää-Dahlqvist
Solbritt Rantapää-Dahlqvist
The presence of rheumatoid factor (RF), anti-carbamylated protein antibodies (anti-CarP) and antibodies against citrullinated protein and peptides (ACPA) precedes the onset of symptoms of rheumatoid arthritis (RA) by several years. Relationships between the development of these antibodies are not obvious. Three isotypes [immunoglobulin A (IgA), IgG and IgM) of RF were analysed in 321 pre-symptomatic individuals who provided 598 samples collected a median of 6.2 (interquartile range 7.2) years before the onset of symptoms, and in 492 population control subjects. All samples were donated to the Biobank of Northern Sweden. RF isotypes were analysed using the EliA system (Phadia GmbH, Freiburg, Germany) with 96 % specificity according to receiver operating characteristic curves. Ten ACPA specificities were analysed using the ImmunoCAP ISAC system, and anti-CCP2 and anti-CarP antibodies were evaluated using enzyme-linked immunosorbent assays. The frequencies of RF isotypes in pre-symptomatic individuals were significantly increased compared with control subjects (p < 0.0001). In samples collected ≥15 years before the onset of symptoms, the IgA-RF isotype was significantly more prevalent than the most frequent ACPAs. Combinations of IgM- and IgA-RF isotypes with ACPA specificities [α-enolase (CEP-1/Eno5–21)], fibrinogen (Fib)β36–52, Fibα580–600, filaggrin (CCP-1/Fil307–324) and anti-CCP2 antibodies were associated with a significantly shorter time to onset of symptoms (p < 0.001–0.05). Using conditional inference tree analysis, anti-CCP2 in combination with anti-filaggrin antibodies gave the highest probability, 97.5 %, for disease development. RF isotypes predicted the development of RA, particularly in combination with ACPA, anti-CCP2 or anti-CarP antibodies. The highest probability for disease development was the presence of anti-CCP2 and anti-filaggrin antibodies.

3 June 2016 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
LJLinda Johansson
Linda Johansson
FPFederico Pratesi
Federico Pratesi
MBMikael Brink
Mikael Brink
LÄLisbeth Ärlestig
Lisbeth Ärlestig
CDClaudia D’aMato
Claudia D’aMato
SRSolbritt Rantapää-Dahlqvist
Solbritt Rantapää-Dahlqvist
Anti-citrullinated-peptide antibodies (ACPA) have been detected in individuals with developing rheumatoid arthritis (RA) before the onset of symptom, with an initially limited spectrum of reactivities that gradually broadens. The aim was to analyze the evolution of ACPA response pre-dating symptom onset, using four selected citrullinated exogenous and endogenous antigens. A cohort of 521 individuals sampled before symptoms of RA appeared and 272 population controls were identified from the Biobank of Northern Sweden; 241 samples from patients with early RA were also collected. ACPA were detected by ELISA on viral citrullinated peptides (VCP) derived from Epstein-Barr-virus nuclear antigen (EBNA)1 and EBNA2 (VCP1 and VCP2) and histone-4-derived citrullinated peptides (HCP1 and HCP2). In pre-symptomatic individuals vs. patients with early RA, anti-VCP1 antibodies were detected in 10.4 % vs. 36.1 %, anti-VCP2 in 17.1 % vs. 52.3 %, anti-HCP1 in 10.2 % vs. 37.3 %, and anti-HCP2 in 16.3 % vs. 48.5 %, respectively. Anti-VCP and anti-HCP concentrations were significantly increased in pre-symptomatic individuals vs. controls (p < 0.001) and were increased approaching symptom onset. Anti-VCP and anti-HCP appeared simultaneously (median (IQR) 5.3 (6) years before symptom onset) and in combination yielded a high-risk ratio for disease development (OR = 8.0–18.9). Anti-VCP2 and anti-HCP2 antibodies were associated with HLA-DRB1*0401 in pre-symptomatic individuals. Three peptidylarginine deiminase (PAD)I3/PADI4 single nucleotide polymorphisms (SNPs) were significantly associated with anti-HCP1. Anti-VCP and anti-HCP antibodies pre-date symptom onset and predict disease development, but no hierarchy of citrullinated epitopes can be identified. These results suggest that no inciting citrullinated antigen so far described is common to all patients with RA. The association between PADI3/PADI4 polymorphism and anti-HCP1 antibodies suggests a novel link between deimination and production of ACPA.